Association of triglyceride-glucose index with long-term prognosis in advanced hepatocellular carcinoma patients receiving immunotherapy and targeted therapy

Table 5 Comparison of features between the training and validation sets, n (%)

Characteristic	Test (n = 84)	Train (n = 194)	χ2	P value
Age, years			0.10	0.747
< 60	39 (46.43)	86 (44.33)
≥ 60	45 (53.57)	108 (55.67)
Sex			0.79	0.375
Female	46 (54.76)	95 (48.97)
Male	38 (45.24)	99 (51.03)
BMI, kg/m2			0.81	0.369
< 25	64 (76.19)	157 (80.39)
≥ 25	20 (23.81)	37 (19.07)
TyG index			0.02	0.894
Low	41 (48.81)	93 (47.94)
High	43 (51.19)	101 (47.94)
HBV-DNA			0.80	0.371
HBV ≤ 2000	41 (48.81)	106 (54.64)
HBV > 2000	43 (51.19)	88 (45.36)
HBe			0.08	0.778
Negative	62 (73.81)	140 (72.16)
Positive	22 (26.19)	54 (27.84)
ECOG			0.07	0.785
0-1	54 (64.29)	128 (65.98)
2	30 (35.71)	85 (34.02)
Child-Pugh score			0.00	0.961
B	44 (52.38)	101 (56.19)
C	40 (47.62)	93 (43.81)
PVTT			1.55	0.213
No	60 (71.43)	152 (78.35)
Yes	24 (28.57)	42 (21.65)
Diabetes			2.41	0.121
No	59 (70.24)	153 (83.15)
Yes	25 (29.76)	41 (16.85)
AFP, ng/mL			0.65	0.420
< 1210	35 (41.67)	91 (46.91)
≥ 1210	49 (58.33)	103 (53.09)
BCLC class			1.58	0.208
B	39 (46.43)	106 (54.64)
C	45 (53.57)	88 (45.36)
Metastasis			1.66	0.197
No	62 (73.81)	128 (65.98)
Yes	22 (26.19)	66 (34.02)
ALT			0.76	0.384
≤ 40	42 (50.00)	108 (55.67)
> 40	42 (50.00)	86 (44.33)
Total bilirubin			0.22	0.642
≤ 34	54 (64.29)	119 (61.34)
> 34	30 (35.71)	75 (38.66)
Cirrhosis			0.07	0.798
No	46 (54.76)	103 (53.09)
Yes	38 (45.24)	91 (46.91)
Interventional			0.57	0.451
No	50 (59.52)	106 (54.64)
Yes	34 (40.48)	88 (45.36)
Hypertensive			0.13	0.720
No	46 (54.76)	123 (63.40)
Yes	38 (45.24)	50 (36.60)

BMI: Body mass index; TyG: Triglyceride-glucose; HBV: Hepatitis B virus; HBe: Hepatitis B e; ECOG: Eastern Cooperative Oncology Group; PVTT: Portal vein tumor thrombosis; AFP: Alpha-fetoprotein; BCLC: Barcelona Clinic Liver Cancer; ALT: Alanine aminotransferase.